CA1312030C
(en)
*
|
1987-11-18 |
1992-12-29 |
Brian Maiorella |
Method to increase antibody titer
|
US6238891B1
(en)
|
1987-11-18 |
2001-05-29 |
Cetus Oncology Corporation |
Method of increasing product expression through solute stress
|
US6048728A
(en)
*
|
1988-09-23 |
2000-04-11 |
Chiron Corporation |
Cell culture medium for enhanced cell growth, culture longevity, and product expression
|
ATE135397T1
(de)
*
|
1988-09-23 |
1996-03-15 |
Cetus Oncology Corp |
Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
|
GB9004390D0
(en)
*
|
1990-02-27 |
1990-04-25 |
Ici Plc |
Process
|
US5122469A
(en)
*
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
CA2089653A1
(en)
*
|
1991-06-17 |
1992-12-18 |
Dennis M. Disorbo |
Media concentrate technology
|
GB9118664D0
(en)
*
|
1991-08-30 |
1991-10-16 |
Celltech Ltd |
Cell culture
|
DK0643772T3
(da)
|
1992-06-03 |
1998-02-02 |
Genentech Inc |
Glycosyleringsvarianter af vævsplasminogenaktivator med forbedrede terapeutiske egenskaber
|
GB9215834D0
(en)
|
1992-07-24 |
1992-09-09 |
Celltech Ltd |
Cell culture
|
USH1532H
(en)
*
|
1993-11-03 |
1996-05-07 |
Genetics Institute, Inc. |
Adaption of mammalian cell lines to high cell densities
|
US5856179A
(en)
|
1994-03-10 |
1999-01-05 |
Genentech, Inc. |
Polypeptide production in animal cell culture
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US5830761A
(en)
*
|
1995-06-07 |
1998-11-03 |
Genetics Institute, Inc. |
Medium and methods for culturing mammalian cho cells
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
DE69737457T2
(de)
|
1997-01-31 |
2007-11-29 |
Genentech, Inc., South San Francisco |
O-fukosyltransferase
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
TR199902818T2
(xx)
|
1997-04-07 |
2000-05-22 |
Genentech, Inc. |
Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
PT1007546E
(pt)
|
1997-08-27 |
2009-04-24 |
Childrens Hosp & Res Ct Oak |
Compostos miméticos moleculares de epítopos de meningococos do serogrupo b
|
US6528286B1
(en)
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
EP1953229A3
(en)
|
1998-10-15 |
2008-12-24 |
Novartis Vaccines and Diagnostics, Inc. |
Metastatic breast and colon cancer regulated genes
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
DK1141331T3
(da)
|
1998-12-16 |
2009-01-05 |
Novartis Vaccines & Diagnostic |
Human cyclinafhængig kinase (hPNQALRE)
|
ES2694002T3
(es)
|
1999-01-15 |
2018-12-17 |
Genentech, Inc. |
Polipéptido que comprende una región Fc de IgG1 humana variante
|
WO2000065070A2
(en)
|
1999-04-26 |
2000-11-02 |
Genentech, Inc. |
Cell culture process for glycoproteins
|
CH694589A5
(de)
|
1999-06-25 |
2005-04-15 |
Genentech Inc |
Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern.
|
CA2383642C
(en)
|
1999-10-14 |
2014-03-25 |
Clontech Laboratories, Inc. |
Anthozoa derived chromophores/fluorophores and methods for using the same
|
US7608681B2
(en)
|
1999-12-24 |
2009-10-27 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
EP1757701A1
(en)
|
1999-12-24 |
2007-02-28 |
Genentech, Inc. |
Methods and compositions for prolonging elimination half-times of bioactive compounds
|
EP1248841B1
(en)
|
2000-01-10 |
2008-07-23 |
Novartis Vaccines and Diagnostics, Inc. |
Genes differentially expressed in breast cancer
|
PL357939A1
(en)
|
2000-04-11 |
2004-08-09 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
AU2001271614B2
(en)
|
2000-07-03 |
2007-05-31 |
Catalent Pharma Solutions, Llc |
Host cells containing multiple integrating vectors
|
CA2413156C
(en)
|
2000-07-03 |
2009-08-18 |
Gala Design, Inc. |
Expression vectors
|
ES2317924T3
(es)
|
2000-07-27 |
2009-05-01 |
Genentech, Inc. |
Administracion secuencial de cpt-11 y polipeptido apo-2l.
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
WO2003000113A2
(en)
|
2001-06-20 |
2003-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
MXPA04001566A
(es)
|
2001-08-27 |
2004-05-17 |
Genentech Inc |
Un sistema para expresion y ensamblado de anticuerpos.
|
KR101008785B1
(ko)
|
2001-08-29 |
2011-01-14 |
제넨테크, 인크. |
유사분열촉진 활성을 가진 Bv8 핵산 및 폴리펩티드
|
JP2005536439A
(ja)
|
2001-09-18 |
2005-12-02 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断及び治療のための組成物と方法
|
WO2003088808A2
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
AU2002357322A1
(en)
|
2001-12-19 |
2003-07-09 |
The University Of Chicago |
Rapidly maturing fluorescent proteins and methods for using the same
|
NZ556415A
(en)
|
2002-01-02 |
2009-02-28 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
US7384738B2
(en)
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US20040038304A1
(en)
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
WO2003103725A1
(en)
|
2002-06-07 |
2003-12-18 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
DK2263691T3
(da)
|
2002-07-15 |
2012-10-22 |
Hoffmann La Roche |
Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4)
|
LT1543038T
(lt)
|
2002-09-11 |
2017-07-10 |
Genentech, Inc. |
Baltymo gryninimas
|
AU2004205684A1
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
NZ541480A
(en)
|
2003-03-12 |
2008-03-28 |
Genentech Inc |
Use of Bv8 and/or EG-VEGF to promote hematopoiesis
|
RS20150135A1
(en)
|
2003-05-30 |
2015-08-31 |
Genentech Inc. |
TREATMENT WITH ANTI-VEGF ANTIBODIES
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
ZA200604864B
(en)
|
2003-12-19 |
2007-10-31 |
Genentech Inc |
Monovalent antibody fragments useful as therapeutics
|
RU2401277C2
(ru)
|
2004-01-07 |
2010-10-10 |
Чирон Корпорейшн |
Не мышиное анти-m-csf-антитело (варианты), его получение и использование
|
WO2005076938A2
(en)
|
2004-02-11 |
2005-08-25 |
Massachusetts Institute Of Technology |
Multi-polymer-coated magnetic nanoclusters
|
DK1736541T3
(da)
|
2004-03-29 |
2013-05-06 |
Galpharma Co Ltd |
Nyt modificeret galectin 9-protein og anvendelse heraf
|
WO2005100387A1
(en)
|
2004-04-07 |
2005-10-27 |
The University Of Chicago |
Monomeric red fluorescent proteins
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
WO2005108424A1
(en)
|
2004-05-06 |
2005-11-17 |
Genentech, Inc. |
Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
|
KR101254815B1
(ko)
|
2004-07-20 |
2013-09-03 |
제넨테크, 인크. |
안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
ES2555355T3
(es)
|
2004-09-03 |
2015-12-30 |
Genentech, Inc. |
Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
|
US7741096B2
(en)
|
2004-12-10 |
2010-06-22 |
Genentech, Inc. |
Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
|
DK1841793T3
(da)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
EA017874B1
(ru)
|
2005-03-21 |
2013-03-29 |
Вайробей, Инк. |
Производные альфа-кетоамидов в качестве ингибиторов цистеинпротеаз
|
JP4841618B2
(ja)
|
2005-03-23 |
2011-12-21 |
バイオ−ラッド ラボラトリーズ インコーポレーティッド |
タンパク質を精製するための方法
|
ES2772674T3
(es)
|
2005-05-12 |
2020-07-08 |
Zymogenetics Inc |
Composiciones y métodos para modular respuestas inmunitarias
|
EP2311876A3
(en)
|
2005-07-28 |
2011-04-27 |
Novartis AG |
M-CSF-specific monoclonal antibody and uses thereof
|
EP1919931A4
(en)
|
2005-08-31 |
2010-01-20 |
Univ California |
CELLULAR LIBRARIES OF PEPTIDE SEQUENCES (CLIPS) AND METHODS OF USE THEREOF
|
WO2007053732A2
(en)
|
2005-11-01 |
2007-05-10 |
Mayo Foundation For Medical Education And Research |
Promoter polymorphisms of the blys gene and use in diagnostic methods
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
EP3023497A1
(en)
|
2005-11-18 |
2016-05-25 |
Glenmark Pharmaceuticals S.A. |
Anti-alpha2 integrin antibodies and their uses
|
US8957187B2
(en)
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
CN105859886A
(zh)
|
2005-12-02 |
2016-08-17 |
健泰科生物技术公司 |
牵涉与il-22和il-22r结合的抗体的组合物和方法
|
EP1973948B1
(en)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
KR101589391B1
(ko)
|
2006-01-05 |
2016-01-29 |
제넨테크, 인크. |
항-ephb4 항체 및 그의 사용 방법
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
EP2389946A1
(en)
|
2006-03-23 |
2011-11-30 |
Novartis AG |
Anti-tumor cell antigen antibody therapeutics
|
TWI392684B
(zh)
|
2006-04-05 |
2013-04-11 |
Abbott Biotech Ltd |
抗體之純化
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
CN103030696B
(zh)
|
2006-05-30 |
2016-09-28 |
健泰科生物技术公司 |
抗体和免疫偶联物及其用途
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
JP5829004B2
(ja)
|
2006-06-30 |
2015-12-09 |
ノボ・ノルデイスク・エー/エス |
抗nkg2a抗体とその使用
|
EP2061897B1
(en)
*
|
2006-07-27 |
2020-03-25 |
Wyeth LLC |
High-cell density fed-batch fermentation process for producing recombinant protein
|
JP5406027B2
(ja)
|
2006-08-04 |
2014-02-05 |
ノバルティス アーゲー |
EphB3特異的抗体およびその使用
|
KR20140033241A
(ko)
|
2006-08-18 |
2014-03-17 |
노바르티스 아게 |
Prlr 특이적 항체 및 그 용도
|
US8623830B2
(en)
|
2006-09-12 |
2014-01-07 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions containing α-1-antitrypsin and methods for use
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
JP5795833B2
(ja)
|
2006-10-27 |
2015-10-14 |
エルパス・インコーポレイテッドLpath, Inc. |
スフィンゴシン−1−リン酸と結合させるための組成物および方法
|
HUE034263T2
(en)
|
2006-10-27 |
2018-02-28 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
US8614103B2
(en)
|
2006-10-27 |
2013-12-24 |
Lpath, Inc. |
Compositions and methods for treating sphingosine-1-phosphate (S1P) related ocular diseases and conditions
|
AU2007319359A1
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
AU2007329307B2
(en)
|
2006-12-07 |
2012-08-02 |
Novartis Ag |
Antagonist antibodies against EphB3
|
TW200844110A
(en)
|
2007-01-11 |
2008-11-16 |
Univ Marburg Philipps |
Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
|
EP2120915B1
(en)
|
2007-01-22 |
2011-09-28 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
EP2468776A3
(en)
|
2007-02-09 |
2012-11-14 |
Genentech, Inc. |
Anti-Robo4 antibodies and uses therefor
|
JP5761915B2
(ja)
|
2007-02-22 |
2015-08-12 |
ジェネンテック, インコーポレイテッド |
炎症性腸疾患の検出方法
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
JP5889527B2
(ja)
|
2007-04-12 |
2016-03-22 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
癌療法のためのabcb5標的化
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
CA2724432A1
(en)
|
2007-05-30 |
2008-12-11 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
KR20150029002A
(ko)
|
2007-06-07 |
2015-03-17 |
제넨테크, 인크. |
보체-관련 장애의 예방 및 치료를 위한 C3b 항체 및 방법
|
KR101643514B1
(ko)
|
2007-07-09 |
2016-07-27 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
ES2434829T3
(es)
|
2007-09-05 |
2013-12-17 |
Genentech, Inc. |
Péptidos que contienen arginina C-terminal biológicamente activos
|
JP5496897B2
(ja)
|
2007-10-04 |
2014-05-21 |
ザイモジェネティクス, インコーポレイテッド |
B7ファミリーメンバーのzB7H6ならびに関連する組成物および方法
|
KR20150008503A
(ko)
|
2007-10-30 |
2015-01-22 |
제넨테크, 인크. |
양이온 교환 크로마토그래피에 의한 항체 정제
|
WO2009059305A2
(en)
|
2007-11-01 |
2009-05-07 |
The University Of Chicago |
Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
|
SG185972A1
(en)
|
2007-11-07 |
2012-12-28 |
Genentech Inc |
Compositions and methods for treatment of microbial disorders
|
JP2011503094A
(ja)
|
2007-11-08 |
2011-01-27 |
ジェネンテック, インコーポレイテッド |
抗b因子抗体およびそれらの使用
|
WO2009073511A2
(en)
|
2007-11-30 |
2009-06-11 |
Mayo Foundation For Medical Education And Research |
Polymorphisms of the blys gene and use in diagnostic methods
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
US8414893B2
(en)
|
2007-12-21 |
2013-04-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
MX2010008096A
(es)
|
2008-01-25 |
2010-09-22 |
Amgen Inc |
Anticuerpos de ferroportina y metodos de uso.
|
WO2009099728A1
(en)
|
2008-01-31 |
2009-08-13 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
EP2620448A1
(en)
|
2008-05-01 |
2013-07-31 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
JP5836800B2
(ja)
|
2008-05-06 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
親和性成熟CRIg変異体
|
JP2011520961A
(ja)
|
2008-05-22 |
2011-07-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
多価フィブロネクチンをベースとする足場ドメインタンパク質
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
US10927144B2
(en)
|
2008-08-14 |
2021-02-23 |
Genentech, Inc. |
Methods for removing a contaminant using indigenous protein displacement ion exchange membrane chromatography
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
JP4883067B2
(ja)
|
2008-09-29 |
2012-02-22 |
株式会社日立プラントテクノロジー |
培養装置及び培養方法
|
SG10201702922VA
(en)
|
2008-10-20 |
2017-06-29 |
Abbvie Inc |
Isolation and purification of antibodies using protein a affinity chromatography
|
MX2011004306A
(es)
|
2008-10-22 |
2011-07-28 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
EP2346903A1
(en)
|
2008-11-06 |
2011-07-27 |
Glenmark Pharmaceuticals S.A. |
Treatment with anti-alpha2 integrin antibodies
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
TWI686405B
(zh)
|
2008-12-09 |
2020-03-01 |
建南德克公司 |
抗pd-l1抗體及其於增進t細胞功能之用途
|
US10080578B2
(en)
|
2008-12-16 |
2018-09-25 |
Nico Corporation |
Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
|
MX347291B
(es)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
KR101822663B1
(ko)
|
2009-03-25 |
2018-01-29 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
RU2587621C2
(ru)
|
2009-04-01 |
2016-06-20 |
Дженентек, Инк. |
АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
KR101431318B1
(ko)
|
2009-04-02 |
2014-08-20 |
로슈 글리카트 아게 |
전장 항체 및 단일쇄 fab 단편을 포함하는 다중특이성 항체
|
WO2010118243A2
(en)
|
2009-04-08 |
2010-10-14 |
Genentech, Inc. |
Use of il-27 antagonists to treat lupus
|
MX2012000705A
(es)
|
2009-07-15 |
2012-03-07 |
Abbott Lab |
Mejoramiento de produccion celular a traves de mecanotransduccion.
|
WO2011011689A2
(en)
|
2009-07-23 |
2011-01-27 |
The Regents Of The University Of Michigan |
Method for enzymatic production of decarboxylated polyketides and fatty acids
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
KR20180010324A
(ko)
|
2009-08-11 |
2018-01-30 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
EP2473617B1
(en)
|
2009-09-01 |
2020-02-26 |
F.Hoffmann-La Roche Ag |
Enhanced protein purification through a modified protein a elution
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
AU2010296018B2
(en)
|
2009-09-16 |
2016-05-05 |
Genentech, Inc. |
Coiled coil and/or tether containing protein complexes and uses thereof
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
BR112012009245A2
(pt)
|
2009-10-19 |
2019-09-24 |
Genentech Inc |
''anticorpo,polinucleotídeo,celula hospedeira,método para fabricar um anticorpo,imunoconjugado,formulação farmacêutica e uso do anticorpo''
|
CN104744560A
(zh)
|
2009-10-20 |
2015-07-01 |
Abbvie公司 |
使用蛋白a亲和色谱法分离和纯化抗-il-13抗体
|
WO2011050194A1
(en)
|
2009-10-22 |
2011-04-28 |
Genentech, Inc. |
Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック, インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
AU2010310589A1
(en)
|
2009-10-22 |
2012-05-10 |
Genentech, Inc. |
Modulation of axon degeneration
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
US8524458B2
(en)
|
2009-11-09 |
2013-09-03 |
Abbvie Inc. |
Secretory protein biomarkers for high efficiency protein expression
|
JP2013510871A
(ja)
|
2009-11-12 |
2013-03-28 |
ジェネンテック, インコーポレイテッド |
樹状突起棘の密度を促す方法
|
TW201129379A
(en)
|
2009-11-20 |
2011-09-01 |
Amgen Inc |
Anti-Orai1 antigen binding proteins and uses thereof
|
US9096879B2
(en)
|
2009-11-24 |
2015-08-04 |
Biogen Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
MX2012006072A
(es)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
SG2014011340A
(en)
|
2009-12-21 |
2014-07-30 |
Genentech Inc |
Antibody formulation
|
MY161868A
(en)
|
2009-12-23 |
2017-05-15 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
RU2015102845A
(ru)
|
2010-02-23 |
2015-06-10 |
Санофи |
АНТИТЕЛА К ИНТЕГРИНУ α2 И ИХ ПРИМЕНЕНИЯ
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
MA34091B1
(fr)
|
2010-03-31 |
2013-03-05 |
Boehringer Ingelheim Int |
Anticorps anti-cd40
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
US20110262965A1
(en)
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
BR112012027001A2
(pt)
|
2010-04-23 |
2016-07-19 |
Genentech Inc |
produção de proteínas heteromultiméricas
|
PT2563906T
(pt)
|
2010-04-26 |
2018-02-16 |
Novartis Ag |
Processo para cultivo de células cho
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
JP5947289B2
(ja)
|
2010-05-10 |
2016-07-06 |
アカデミア シニカAcademia Sinica |
抗インフルエンザ活性を有するザナミビルホスホネート同族体およびインフルエンザウイルスのオセルタミビルに対する感受性の決定
|
ES2573108T3
(es)
|
2010-05-26 |
2016-06-06 |
Bristol-Myers Squibb Company |
Proteínas de armazón a base de fibronectina que tienen estabilidad mejorada
|
JP6050226B2
(ja)
|
2010-05-28 |
2016-12-21 |
ジェネンテック, インコーポレイテッド |
Ldh及びpdhk発現を下方制御することによる乳酸レベルの低下及びポリペプチド生産の増加
|
JP6048973B2
(ja)
|
2010-06-03 |
2016-12-27 |
ジェネンテック, インコーポレイテッド |
抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法
|
AU2011268310A1
(en)
|
2010-06-16 |
2013-01-10 |
Abbvie Inc. |
Comparison of protein samples
|
US9011863B2
(en)
|
2010-07-09 |
2015-04-21 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
US20140072983A1
(en)
|
2010-08-10 |
2014-03-13 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
MX340558B
(es)
|
2010-08-24 |
2016-07-14 |
F Hoffmann-La Roche Ag * |
Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
|
WO2012040041A1
(en)
|
2010-09-20 |
2012-03-29 |
Abbott Laboratories |
Purification of antibodies using simulated moving bed chromatography
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
CA2814029C
(en)
|
2010-10-08 |
2017-05-09 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments associated with immune thrombocytopenia
|
WO2012045273A1
(en)
|
2010-10-08 |
2012-04-12 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments and uses thereof
|
KR101631740B1
(ko)
|
2010-10-08 |
2016-06-17 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 단편의 진단학적 및 치료학적 용도
|
EP2624855B1
(en)
|
2010-10-08 |
2016-12-14 |
Shanghai Kexin Biotech Co., Ltd |
Moesin fragments associated with aplastic anemia
|
CA2814024C
(en)
|
2010-10-08 |
2017-05-09 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin modulators and uses thereof
|
PT2635601T
(pt)
|
2010-11-04 |
2016-09-27 |
Boehringer Ingelheim Int |
Anticorpos anti-il-23
|
SG189475A1
(en)
|
2010-11-05 |
2013-05-31 |
Transbio Ltd |
Markers of endothelial progenitor cells and uses thereof
|
EP2640366A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
US20140066431A1
(en)
|
2010-11-15 |
2014-03-06 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
WO2012071509A2
(en)
|
2010-11-24 |
2012-05-31 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
|
US9505826B2
(en)
|
2010-12-22 |
2016-11-29 |
Teva Pharmaceuticals Australia Pty Ltd |
Modified antibody with improved half-life
|
EP2655413B1
(en)
|
2010-12-23 |
2019-01-16 |
F.Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
KR20140009311A
(ko)
|
2011-01-18 |
2014-01-22 |
암젠 인크 |
Nav1.7 넉아웃 마우스 및 이의 용도
|
RU2018108836A
(ru)
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
EP2683735A1
(en)
|
2011-03-10 |
2014-01-15 |
HCO Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
US20120238730A1
(en)
|
2011-03-15 |
2012-09-20 |
Abbott Laboratories |
Integrated approach to the isolation and purification of antibodies
|
EP2689250A1
(en)
|
2011-03-23 |
2014-01-29 |
AbbVie Inc. |
Methods and systems for the analysis of protein samples
|
AU2012236304C1
(en)
|
2011-03-31 |
2017-01-05 |
Genentech, Inc. |
Methods of administering beta7 integrin antagonists
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
PT2714735T
(pt)
|
2011-06-03 |
2021-10-26 |
Xoma Technology Ltd |
Anticorpos específicos para tgf-beta
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
CA2842481A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
KR102492792B1
(ko)
|
2011-10-11 |
2023-01-30 |
제넨테크, 인크. |
이중특이적 항체의 개선된 어셈블리
|
WO2013067029A2
(en)
|
2011-10-31 |
2013-05-10 |
Bristol-Myers Squibb Company |
Fibronectin binding domains with reduced immunogenicity
|
CA2852994C
(en)
|
2011-11-16 |
2023-02-14 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies
|
EP2785744B1
(en)
|
2011-12-01 |
2017-10-04 |
AP Biosciences, Inc. |
Protein inhibitors to complement and vegf pathways and methods of use thereof
|
BR112014014652B1
(pt)
|
2011-12-16 |
2021-07-13 |
Braskem S.A. |
Método de produção de butadieno e microrganismo geneticamente modificado
|
CN104125963B
(zh)
|
2011-12-22 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
使用离子交换膜层析改进下游蛋白质纯化步骤的方法
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
WO2013106489A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
JP6684490B2
(ja)
|
2012-01-09 |
2020-04-22 |
ザ・スクリップス・リサーチ・インスティテュート |
超長相補性決定領域及びその使用
|
JP2015506950A
(ja)
|
2012-01-31 |
2015-03-05 |
ジェネンテック, インコーポレイテッド |
抗ig−em1’抗体およびそれを用いる方法
|
BR112014019579A2
(pt)
|
2012-02-10 |
2019-10-15 |
Genentech, Inc |
Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
|
WO2013126813A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
CA2870769C
(en)
|
2012-04-27 |
2021-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Vascular endothelial growth factor antagonists and methods for their use
|
EP4039275A1
(en)
|
2012-05-03 |
2022-08-10 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
TW201348247A
(zh)
|
2012-05-21 |
2013-12-01 |
Abbvie Inc |
利用蛋白質a親和性層析之非人類抗體之新穎純化
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
MX2014014065A
(es)
|
2012-06-27 |
2015-02-04 |
Hoffmann La Roche |
Metodo para la seleccion y produccion de moleculas terapeuticas hechas a la medida, selectivas y multiespecificas que comprenden al menos dos diferentes entidades de direccionamiento y usos de las mismas.
|
EP2867254B1
(en)
|
2012-06-27 |
2017-10-25 |
F. Hoffmann-La Roche AG |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
WO2014001324A1
(en)
|
2012-06-27 |
2014-01-03 |
Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
WO2014031762A1
(en)
|
2012-08-21 |
2014-02-27 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
BR112015007528A2
(pt)
|
2012-10-05 |
2018-09-04 |
Genentech Inc |
método para prever a resposta, para prever a responsividade, para identificar e para tratar um paciente que tem uma disfunção inflamatória gastrointestinal.
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
US20150361159A1
(en)
|
2013-02-01 |
2015-12-17 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
CA2904169C
(en)
|
2013-03-13 |
2021-12-07 |
Genentech, Inc. |
Formulations with reduced oxidation
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
MX365567B
(es)
|
2013-03-13 |
2019-06-07 |
Genentech Inc |
Formulaciones de anticuerpo.
|
WO2014160495A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Formulations with reduced oxidation
|
LT2968461T
(lt)
|
2013-03-13 |
2022-12-27 |
Genzyme Corporation |
Sulieti baltymai, apimantys pdgf ir vegf surišančius fragmentus, ir jų panaudojimo būdai
|
US20140314778A1
(en)
|
2013-03-13 |
2014-10-23 |
Genentech, Inc. |
Formulations with reduced oxidation
|
EP2970375A1
(en)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
EP2836515A1
(en)
|
2013-03-14 |
2015-02-18 |
AbbVie Inc. |
Low acidic species compositions and methods for producing and using the same
|
CN105121628B
(zh)
|
2013-03-15 |
2020-03-24 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
RU2015136856A
(ru)
|
2013-03-15 |
2017-04-21 |
ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед |
Применение промежуточных соединений цикла трикарбоновых кислот (ТСА) для контроля образования аммиака в культуре клеток
|
KR102202476B1
(ko)
|
2013-03-15 |
2021-01-12 |
제넨테크, 인크. |
세포 배양 배지 및 항체 생산 방법
|
WO2014146575A1
(en)
|
2013-03-19 |
2014-09-25 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
BR112015024856A2
(pt)
|
2013-03-27 |
2018-04-17 |
Genentech Inc |
métodos de determinação ou de monitoramento
|
US9920096B2
(en)
|
2013-06-25 |
2018-03-20 |
Sepia Pesquisa E Desenvolvimento |
Bradykinin receptor modulators and use thereof
|
US10086054B2
(en)
|
2013-06-26 |
2018-10-02 |
Academia Sinica |
RM2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
US20160237399A1
(en)
|
2015-02-18 |
2016-08-18 |
Biogen Ma Inc. |
Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
|
PL3036320T3
(pl)
|
2013-08-19 |
2021-11-02 |
Biogen Ma Inc. |
Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
|
US11078464B2
(en)
|
2013-08-30 |
2021-08-03 |
Amgen Inc. |
High titer recombinant AAV vector production in adherent and suspension cells
|
EP3041484B1
(en)
|
2013-09-06 |
2021-03-03 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
BR112016006321B1
(pt)
|
2013-09-23 |
2022-11-16 |
Braskem S.A |
Enzima engenheirada tendo especificidade de substrato aceto acetil-coa e atividade aceto acetil-coa específica de hidrolase, micro-organismo modificado, e, processo de produção de um ou mais produtos a partir de uma fonte de carbono fermentável
|
MA38960A1
(fr)
|
2013-09-27 |
2017-10-31 |
Genentech Inc |
Formulations d'anticorps anti-pdl1
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
CA2926087C
(en)
|
2013-10-10 |
2023-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
WO2015070068A1
(en)
|
2013-11-07 |
2015-05-14 |
Abbvie Inc. |
Isolation and purification of antibodies
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CA2930687C
(en)
|
2013-11-15 |
2024-04-23 |
Genentech, Inc. |
Methods for viral inactivation using eco-friendly detergents
|
HUE047283T2
(hu)
|
2013-12-09 |
2020-04-28 |
Allakos Inc |
Anti-SIGLEC-8 antitestek és eljárások az alkalmazásukra
|
EP3527587A1
(en)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists
|
WO2015095410A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
|
EP3083686B2
(en)
|
2013-12-17 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
US20160289633A1
(en)
|
2013-12-20 |
2016-10-06 |
Biogen Ma Inc. |
Use of Perfusion Seed Cultures to Improve Biopharmaceutical Fed-Batch Production Capacity and Product Quality
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
EA033604B1
(ru)
|
2014-01-31 |
2019-11-08 |
Boehringer Ingelheim Int |
Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
JP6825909B2
(ja)
|
2014-02-28 |
2021-02-03 |
アラコス インコーポレイテッド |
シグレック−8関連疾患を処置するための方法および組成物
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
IL275497B
(en)
|
2014-03-20 |
2022-09-01 |
Bristol Myers Squibb Co |
Serum proteins with type iii fibronectin binding domains
|
CA2943228C
(en)
|
2014-03-20 |
2023-03-14 |
Bristol-Myers Squibb Company |
Stabilized fibronectin based scaffold molecules
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
MX2016012288A
(es)
|
2014-03-25 |
2017-01-23 |
Genentech Inc |
Metodos para preparar un poloxamero para usar en medio de cultivo celular.
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
AR099856A1
(es)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
KR102603417B1
(ko)
|
2014-05-06 |
2023-11-20 |
제넨테크, 인크. |
포유동물 세포를 사용한 이종다량체 단백질의 생산
|
KR20170003720A
(ko)
|
2014-05-27 |
2017-01-09 |
아카데미아 시니카 |
항-cd20 글리코항체 및 이의 용도
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
KR102576850B1
(ko)
|
2014-05-27 |
2023-09-11 |
아카데미아 시니카 |
박테로이드 기원의 푸코시다제 및 이의 사용 방법
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
CA2950433A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
EP3149187B1
(en)
|
2014-05-30 |
2020-04-29 |
Braskem S.A. |
Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
|
WO2015198320A1
(en)
|
2014-06-24 |
2015-12-30 |
Insight Biopharmaceuticals Ltd. |
Methods of purifying antibodies
|
US20170226552A1
(en)
|
2014-07-03 |
2017-08-10 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
RU2714759C2
(ru)
|
2014-07-09 |
2020-02-19 |
Дженентек, Инк. |
Корректировка ph для улучшения размораживания банков клеток
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
ES2753551T3
(es)
|
2014-07-22 |
2020-04-13 |
Sutro Biopharma Inc |
Anticuerpos anti-cd74, composiciones que comprenden anticuerpos anti-CD74 y procedimientos de uso de los anticuerpos anti-CD74
|
EP3172339A1
(en)
|
2014-07-24 |
2017-05-31 |
Boehringer Ingelheim International GmbH |
Biomarkers useful in the treatment of il-23a related diseases
|
JP6899321B2
(ja)
|
2014-09-08 |
2021-07-07 |
アカデミア シニカAcademia Sinica |
糖脂質を使用するヒトiNKT細胞活性化
|
JP7072384B2
(ja)
|
2014-09-15 |
2022-05-20 |
ジェネンテック, インコーポレイテッド |
抗体製剤
|
JP6956631B2
(ja)
|
2014-09-15 |
2021-11-02 |
アムジェン インコーポレイテッド |
二重特異性抗cgrp受容体/pac1受容体抗原結合タンパク質及びその使用
|
US10463716B2
(en)
|
2014-10-13 |
2019-11-05 |
University Of Maryland, Baltimore |
Methods for treating cardiovascular dysfunction and improving fluid homeostasis with Elabela peptide hormone
|
ES2962385T3
(es)
|
2014-10-15 |
2024-03-18 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
WO2016073789A2
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
RU2758608C2
(ru)
|
2014-11-19 |
2021-11-01 |
Конинклейке Филипс Н.В. |
Способ диагностики с использованием hnl
|
WO2016087416A1
(en)
|
2014-12-03 |
2016-06-09 |
F. Hoffmann-La Roche Ag |
Multispecific antibodies
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015378564A1
(en)
|
2015-01-24 |
2017-07-13 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
WO2016123593A1
(en)
|
2015-01-30 |
2016-08-04 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
EP3253784B1
(en)
|
2015-02-04 |
2020-05-06 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
CN107206081A
(zh)
|
2015-02-04 |
2017-09-26 |
勃林格殷格翰国际有限公司 |
治疗炎性疾病的方法
|
EP3978530A1
(en)
|
2015-02-26 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Integrin beta7 antagonists and methods of treating crohn's disease
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
CA2981204C
(en)
|
2015-03-31 |
2023-09-19 |
Novimmune Sa |
Method for optimizing the assembly and production of hetero-multimeric protein complexes
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
HRP20211980T1
(hr)
|
2015-04-07 |
2022-04-01 |
Alector Llc |
Protutijela protiv sortilina i postupci njihove upotrebe
|
WO2016164608A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
AU2016247921A1
(en)
|
2015-04-14 |
2017-08-31 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
CA2980189A1
(en)
|
2015-04-24 |
2016-10-27 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
KR20180002782A
(ko)
|
2015-05-06 |
2018-01-08 |
얀센 바이오테크 인코포레이티드 |
전립선 특이적 막 항원(psma) 이중특이성 결합제 및 그의 용도
|
CN108064170B
(zh)
|
2015-05-29 |
2022-07-15 |
豪夫迈·罗氏有限公司 |
癌症中pd-l1启动子甲基化
|
US10696745B2
(en)
|
2015-06-11 |
2020-06-30 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-PD-L1 antibodies
|
WO2016197491A1
(en)
|
2015-06-12 |
2016-12-15 |
Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences |
A three-dimensional tissue scaffold with stem cell attracting element and use thereof
|
US10774145B2
(en)
|
2015-06-17 |
2020-09-15 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
ES2828694T3
(es)
|
2015-07-29 |
2021-05-27 |
Allergan Inc |
Anticuerpos sólo de cadena pesada frente a ANG-2
|
TW202330904A
(zh)
|
2015-08-04 |
2023-08-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017024285A2
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
UA124379C2
(uk)
|
2015-08-11 |
2021-09-08 |
Усі Байолоджікс Айрленд Лімітед |
Нові антитіла проти білка pd-1
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
US10308711B2
(en)
|
2015-08-14 |
2019-06-04 |
Allergan, Inc. |
Heavy chain only antibodies to PDGF
|
CN108026180B
(zh)
|
2015-08-28 |
2022-06-07 |
豪夫迈·罗氏有限公司 |
抗羟腐胺赖氨酸抗体及其用途
|
US10935544B2
(en)
|
2015-09-04 |
2021-03-02 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
US11591382B2
(en)
|
2015-09-22 |
2023-02-28 |
Genentech, Inc. |
Expression of Fc-containing proteins
|
ES2967078T3
(es)
|
2015-09-23 |
2024-04-25 |
Bristol Myers Squibb Co |
Dominios de fibronectina de tipo III de unión a seroalbúmina con velocidad de disociación rápida
|
EP3733698A1
(en)
|
2015-09-23 |
2020-11-04 |
Bristol-Myers Squibb Company |
Glypican-3 binding fibronectin based scafflold molecules
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3925970A1
(en)
|
2015-11-02 |
2021-12-22 |
F. Hoffmann-La Roche AG |
Methods of making fucosylated and afucosylated forms of a protein
|
EP3377533A2
(en)
|
2015-11-19 |
2018-09-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
MA43567A
(fr)
|
2015-12-15 |
2018-11-14 |
Amgen Inc |
Anticorps pacap et leurs utilisations
|
CA3007419A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
BR112018013071A2
(pt)
|
2015-12-30 |
2018-12-11 |
Genentech Inc |
uso de derivados de triptofano para formulações de proteínas
|
IL259588B2
(en)
|
2016-01-08 |
2023-09-01 |
Hoffmann La Roche |
Methods for the treatment of cea-positive cancer using pd-1 spindle-binding antagonists and bispecific antibodies against anti-cea and anti-cd3
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
US11028410B2
(en)
|
2016-01-27 |
2021-06-08 |
Just-Evotec Biologics, Inc. |
Hybrid promoter and uses thereof
|
EP3411396A1
(en)
|
2016-02-04 |
2018-12-12 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
TW201808978A
(zh)
|
2016-03-08 |
2018-03-16 |
中央研究院 |
N-聚醣及其陣列之模組化合成方法
|
TWI759287B
(zh)
|
2016-03-15 |
2022-04-01 |
日商中外製藥股份有限公司 |
使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
|
EP3433277A4
(en)
|
2016-03-23 |
2020-06-17 |
Mabspace Biosciences (Suzhou) Co., Ltd |
NEW ANTIBODIES AGAINST PD-L1
|
WO2017172990A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
KR102444717B1
(ko)
|
2016-04-15 |
2022-09-16 |
하. 룬드벡 아크티에셀스카브 |
인간화 항-pacap 항체 및 그의 용도
|
MX2018012410A
(es)
|
2016-04-15 |
2019-02-21 |
Boehringer Ingelheim Int |
Metodos para tratar enfermedades inflamatorias.
|
MY200886A
(en)
|
2016-04-22 |
2024-01-22 |
Obi Pharma Inc |
Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens
|
MX2018013683A
(es)
|
2016-05-10 |
2019-06-17 |
Genentech Inc |
Métodos para disminuir los enlaces de trisulfuro durante la producción recombinante de polipéptidos.
|
UA126021C2
(uk)
*
|
2016-06-03 |
2022-08-03 |
Янссен Байотек, Інк. |
Домен фібронектину типу ііі, що зв'язується із сироватковим альбуміном
|
EP3472197A1
(en)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
TWI798179B
(zh)
|
2016-06-17 |
2023-04-11 |
美商建南德克公司 |
多特異性抗體之純化
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3490592A4
(en)
|
2016-07-27 |
2020-03-25 |
OBI Pharma, Inc. |
IMMUNOGENIC / THERAPEUTIC GLYCAN COMPOSITIONS AND USES THEREOF
|
WO2018023121A1
(en)
|
2016-07-29 |
2018-02-01 |
Obi Pharma, Inc. |
Human antibodies, pharmaceutical compositions and methods
|
WO2018018613A1
(zh)
*
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
JP2019530434A
(ja)
|
2016-08-05 |
2019-10-24 |
ジェネンテック, インコーポレイテッド |
アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
CN109963868B
(zh)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
抗体、结合片段及使用方法
|
CA3036972A1
(en)
|
2016-09-14 |
2018-03-22 |
Janssen Biotech, Inc. |
Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof
|
EP3515950A4
(en)
|
2016-09-20 |
2020-10-28 |
Wuxi Biologics Ireland Limited. |
NEW ANTI-PCSK9 ANTIBODIES
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018071597A1
(en)
|
2016-10-12 |
2018-04-19 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
US20180105588A1
(en)
|
2016-10-14 |
2018-04-19 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
CN110366558A
(zh)
|
2016-10-28 |
2019-10-22 |
班扬生物标记公司 |
针对泛素c末端水解酶l1(uch-l1)和胶质纤维酸性蛋白(gfap)的抗体及相关方法
|
AU2017356317A1
(en)
|
2016-11-14 |
2019-05-30 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
CN116327963A
(zh)
|
2016-11-21 |
2023-06-27 |
济世-伊沃泰克生物制品有限公司 |
一种眼科制剂及其用途
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018156777A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
WO2018166495A1
(en)
|
2017-03-15 |
2018-09-20 |
Tsinghua University |
Novel anti-trkb antibodies
|
EP3601350A1
(en)
|
2017-03-27 |
2020-02-05 |
Boehringer Ingelheim International GmbH |
Anti il-36r antibodies combination therapy
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
MX2019013137A
(es)
|
2017-05-05 |
2020-07-14 |
Allakos Inc |
Metodos y composiciones para tratar enfermedades oculares alergicas.
|
WO2018217944A1
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
KR20200028447A
(ko)
|
2017-07-17 |
2020-03-16 |
얀센 바이오테크 인코포레이티드 |
피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
PL3658589T3
(pl)
|
2017-07-26 |
2024-03-18 |
Forty Seven, Inc. |
Przeciwciała anty-sirp-alfa i powiązane sposoby
|
EP3658588A1
(en)
|
2017-07-26 |
2020-06-03 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
EP3668985B1
(en)
|
2017-08-17 |
2021-06-16 |
Just-Evotec Biologics, Inc. |
Method of purifying glycosylated protein from host cell galectins and other contaminants
|
JP7423513B2
(ja)
|
2017-09-18 |
2024-01-29 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体α抗体コンジュゲート及びその使用
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
CA3081094A1
(en)
|
2017-11-20 |
2019-05-23 |
Alison J. GILLESPIE |
Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
|
AU2018396970A1
(en)
|
2017-12-28 |
2020-08-13 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
JP7339262B2
(ja)
|
2018-01-12 |
2023-09-05 |
アムジェン インコーポレイテッド |
Pac1抗体及びその使用
|
EP3740507A4
(en)
|
2018-01-15 |
2022-08-24 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST PD-1
|
US11667949B2
(en)
|
2018-02-15 |
2023-06-06 |
The Trustees Of Princeton University |
Reporter construct and biosensor for interferon second messenger 2-5A
|
KR20200130831A
(ko)
|
2018-03-14 |
2020-11-20 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
항-클라우딘 18.2 항체
|
JP7438180B2
(ja)
|
2018-03-20 |
2024-02-26 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗lag-3抗体ポリペプチド
|
BR112020018927A2
(pt)
|
2018-03-21 |
2021-01-05 |
ALX Oncology Inc. |
Anticorpos contra proteína alfa reguladora de sinal e métodos de uso
|
EP3774901A1
(en)
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
AU2019245243A1
(en)
|
2018-03-29 |
2020-09-03 |
Genentech, Inc |
Modulating lactogenic activity in mammalian cells
|
EP3774917A4
(en)
|
2018-03-30 |
2022-01-19 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AGAINST LAG-3 AND USES THEREOF
|
SG11202009629YA
(en)
|
2018-04-02 |
2020-10-29 |
Amgen Inc |
Erenumab compositions and uses thereof
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
US20210171610A1
(en)
|
2018-05-02 |
2021-06-10 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
JP7460609B2
(ja)
|
2018-05-14 |
2024-04-02 |
ウェアウルフ セラピューティクス, インコーポレイテッド |
活性化可能なインターロイキン-2ポリペプチド及びその使用方法
|
AU2019271149B2
(en)
|
2018-05-14 |
2023-07-13 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
EP3810653A1
(en)
|
2018-06-23 |
2021-04-28 |
F. Hoffmann-La Roche AG |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
JP2021529754A
(ja)
|
2018-06-29 |
2021-11-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
自己免疫疾患の処置における使用のための抗cd40抗体
|
HUE061841T2
(hu)
|
2018-07-13 |
2023-08-28 |
Alector Llc |
Anti-sortilin antitestek és felhasználásuk módszerei
|
KR102140531B1
(ko)
|
2018-08-07 |
2020-08-04 |
(주)휴온스 |
Gly-Tβ4의 제조방법
|
TW202019478A
(zh)
|
2018-08-08 |
2020-06-01 |
美商建南德克公司 |
色胺酸衍生物及l-甲硫胺酸用於蛋白質調配之用途
|
JP2022500454A
(ja)
|
2018-09-17 |
2022-01-04 |
ストロ バイオファーマ インコーポレーテッド |
抗葉酸受容体抗体コンジュゲートによる併用療法
|
US20210355215A1
(en)
|
2018-09-21 |
2021-11-18 |
Teneobio, Inc. |
Methods for purifying heterodimeric, multispecific antibodies
|
PL3857230T3
(pl)
|
2018-09-21 |
2023-10-16 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
WO2020069133A1
(en)
|
2018-09-27 |
2020-04-02 |
Tizona Therapeutics |
Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
|
WO2020069398A1
(en)
|
2018-09-27 |
2020-04-02 |
Akrevia Therapeutics Inc. |
Masked cytokine polypeptides
|
AU2019365391A1
(en)
|
2018-10-23 |
2021-04-29 |
Consejo Superior De Investigaciones Científicas |
Antibodies specific for glycosylated ApoJ and uses thereof
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
JP2022514082A
(ja)
|
2018-12-21 |
2022-02-09 |
ジェネンテック, インコーポレイテッド |
アポトーシスに耐性のある細胞株を使用してポリペプチドを生成する方法
|
CA3123050A1
(en)
|
2018-12-26 |
2020-07-02 |
City Of Hope |
Activatable masked anti-ctla4 binding proteins
|
CN113330027A
(zh)
|
2019-01-23 |
2021-08-31 |
豪夫迈·罗氏有限公司 |
在真核宿主细胞中产生多聚体蛋白质的方法
|
WO2020168315A1
(en)
|
2019-02-15 |
2020-08-20 |
Just-Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
WO2020185479A1
(en)
|
2019-03-08 |
2020-09-17 |
Boehringer Ingelheim International Gmbh |
Anti-il-36r antibody formulations
|
US20220143094A1
(en)
|
2019-04-19 |
2022-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
JP2022531001A
(ja)
|
2019-05-03 |
2022-07-05 |
セルジーン コーポレーション |
抗bcma抗体コンジュゲート、そのコンジュゲートを含む組成物ならびにそのコンジュゲートの製造および使用方法
|
EP3962951A1
(en)
|
2019-05-03 |
2022-03-09 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
AR122263A1
(es)
|
2019-05-09 |
2022-08-31 |
Genentech Inc |
Métodos para producir anticuerpos
|
US11267880B2
(en)
|
2019-05-09 |
2022-03-08 |
Boehringer Ingelheim International Gmbh |
Anti-Sema3A antibodies and their uses for treating eye or ocular diseases
|
MX2021013766A
(es)
|
2019-05-14 |
2022-02-21 |
Werewolf Therapeutics Inc |
Restos de separacion y metodos de uso de los mismos.
|
KR20220012262A
(ko)
|
2019-05-24 |
2022-02-03 |
산유 바이오파마슈티컬스 씨오., 엘티디. |
신형 cldn18.2 결합분자
|
KR20220016139A
(ko)
|
2019-05-30 |
2022-02-08 |
암젠 인크 |
항체 이량체화를 유도하기 위한 경첩 영역 조작
|
EP3980423A1
(en)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidine-2,4-diamino compounds and antibody conjugates thereof
|
US20220259202A1
(en)
|
2019-06-17 |
2022-08-18 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
JP2022538232A
(ja)
|
2019-06-28 |
2022-09-01 |
アムジエン・インコーポレーテツド |
抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
JP2022542863A
(ja)
|
2019-07-24 |
2022-10-07 |
ハー・ルンドベック・アクチエゼルスカベット |
抗mGluR5抗体及びその使用
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
US20220389099A1
(en)
|
2019-11-04 |
2022-12-08 |
Amgen Inc. |
Methods for treating leukemia
|
US20220389119A1
(en)
|
2019-11-08 |
2022-12-08 |
Amgen Inc. |
ENGINEERING CHARGE PAIR MUTATIONS FOR PAIRING OF HETERO-IgG MOLECULES
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
MX2022007688A
(es)
|
2019-12-20 |
2022-07-19 |
Amgen Inc |
Constructos de anticuerpo multiespecificos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores solidos.
|
WO2021146383A1
(en)
|
2020-01-17 |
2021-07-22 |
BioLegend, Inc. |
Anti-tlr7 agents and compositions and methods for making and using the same
|
CN115916988A
(zh)
|
2020-02-21 |
2023-04-04 |
布拉斯科公司 |
在酵母中生产乙醇和一种或多种副产物
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
CA3169908A1
(en)
|
2020-03-26 |
2021-09-30 |
Genentech, Inc. |
Modified mammalian cells having reduced host cell proteins
|
KR20230002559A
(ko)
|
2020-04-15 |
2023-01-05 |
제넨테크, 인크. |
구리 손실 완화
|
KR20230005172A
(ko)
|
2020-04-24 |
2023-01-09 |
에프. 호프만-라 로슈 아게 |
설프히드릴 화합물 및 이의 유도체를 사용한 효소 및 경로 조절
|
IL298431A
(en)
|
2020-05-26 |
2023-01-01 |
Boehringer Ingelheim Int |
Anti-pd-1 antibodies
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
KR20230026491A
(ko)
|
2020-06-24 |
2023-02-24 |
제넨테크, 인크. |
아폽토시스 내성 세포주
|
EP4200338A1
(en)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
WO2022060901A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
AU2021379598A1
(en)
|
2020-11-10 |
2023-06-08 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
CN112538458A
(zh)
|
2020-11-26 |
2021-03-23 |
北京赛尔湃腾科技咨询合伙企业(有限合伙) |
用于重编程细胞的方法
|
US20220281914A1
(en)
|
2020-12-18 |
2022-09-08 |
Kiniksa Pharmaceuticals, Ltd. |
Protein compositions and methods for producing and using the same
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
US20220251205A1
(en)
|
2021-01-29 |
2022-08-11 |
Merck Sharp & Dohme Corp. |
Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
|
JP2024505674A
(ja)
|
2021-02-05 |
2024-02-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
抗il1rap抗体
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187270A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
KR20230148226A
(ko)
|
2021-03-10 |
2023-10-24 |
이뮤노웨이크 인크. |
면역조절 분자 및 이의 용도
|
CA3215965A1
(en)
|
2021-04-19 |
2022-10-27 |
Amy Shen |
Modified mammalian cells
|
WO2022225921A1
(en)
|
2021-04-20 |
2022-10-27 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
CN117203233A
(zh)
|
2021-04-23 |
2023-12-08 |
美国安进公司 |
抗tslp抗体组合物及其用途
|
EP4332120A1
(en)
|
2021-04-26 |
2024-03-06 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Bispecific antibody-drug conjugate
|
JP2024519205A
(ja)
|
2021-04-30 |
2024-05-09 |
セルジーン コーポレーション |
抗bcma抗体薬物コンジュゲート(adc)をガンマセクレターゼ阻害剤(gsi)と組み合わせて使用する併用療法
|
EP4340876A1
(en)
|
2021-05-19 |
2024-03-27 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
EP4370647A1
(en)
|
2021-07-15 |
2024-05-22 |
Just-Evotec Biologics, Inc. |
Bidirectional tangential flow filtration (tff) perfusion system
|
IL310662A
(en)
|
2021-08-23 |
2024-04-01 |
Immunitas Therapeutics Inc |
Anti-CD161 antibodies and their uses
|
TW202330613A
(zh)
|
2021-11-12 |
2023-08-01 |
美商建南德克公司 |
使用整聯蛋白β7拮抗劑治療克隆氏病之方法
|
WO2023102077A1
(en)
|
2021-12-01 |
2023-06-08 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
WO2023114901A2
(en)
|
2021-12-15 |
2023-06-22 |
Oxford Biomedica Solutions Llc |
Methods and compositions for the production of adeno-associated virus
|
WO2023118312A1
(en)
|
2021-12-22 |
2023-06-29 |
Cdr-Life Ag |
Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
|
US20230227545A1
(en)
|
2022-01-07 |
2023-07-20 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023154305A2
(en)
|
2022-02-10 |
2023-08-17 |
Amgen Inc. |
Antibody protein product expression constructs for high throughput sequencing
|
TW202342740A
(zh)
|
2022-03-07 |
2023-11-01 |
美商奧崔基尼克斯製藥公司 |
改良的批量aav生產系統和方法
|
WO2023172903A1
(en)
|
2022-03-08 |
2023-09-14 |
Amgen Inc. |
Modular vector (modvec) system: a platform for construction of next generation expression vectors
|
WO2023172965A1
(en)
|
2022-03-09 |
2023-09-14 |
Amgen Inc. |
Optimized transfection protocol
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
WO2024006563A1
(en)
|
2022-07-01 |
2024-01-04 |
Sutro Biopharma, Inc. |
Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024040321A1
(en)
|
2022-08-24 |
2024-02-29 |
Braskem S.A. |
Process for the recovery of low-boiling point components from an ethanol stream
|
WO2024044780A1
(en)
|
2022-08-26 |
2024-02-29 |
Sutro Biopharma, Inc. |
Interleukin-18 variants and uses thereof
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024092064A1
(en)
|
2022-10-26 |
2024-05-02 |
Amgen Inc. |
Anti-tslp antibody compositions and uses thereof
|
WO2024098023A2
(en)
|
2022-11-04 |
2024-05-10 |
Sutro Biopharma, Inc. |
Interferon alpha polypeptides and conjugates
|